tetrahydrobiopterin load, lower concentrations of neurotransmitter metabolites, and reduced tyrosine production after an oral phenylalanine load.
The first observation that concerns the lack of response of phenylketonuric children to dietary treatment is that of Mary Efron in 1965 reported by McKusick.' Dr Efron pointed out that phenylketonuria (PKU) seldom affects people of southern Italian origin, but when it does, it is unresponsive to diet and causes death in the first years of life. The observation may have been the result of some type of tetrahydrobiopterin (BH4) deficiency, which was not recognised at that time, as a possible cause of primary hyperphenylalaninaemia. This hypothesis is supported by the recent finding that among people of southern Italian origin the frequency of BH4 deficiency seems higher than in other populations, mainly due to the higher prevalence, and clustering in Sicily, of dihydropteridine reductase (DHPR) [tmol/l) . Difficulty in feeding, extreme truncal hypotonia, and eye deviation had appeared in the first two months of life, and by the fifth month psychomotor deterioration, microcephaly (head circumference below the third centile), repeated daily myoclonic convulsions and hypsarrhythmic activity shown on electroencephalography were present. A phenylalanine restricted diet was started at 10 months, and neurotransmitter treatment was added at 13 months after the diagnosis of DHPR deficiency. Despite the severity of the clinical picture and the delay in beginning treatment, the patient slowly improved. Convulsions stopped within six months with electroencephalography giving normal results. Motor disabilities and behavioural abnormalities diminished and head circumference increased (it is now over the 10th centile). At 2 years 6 months of age the patient started walking and speaking some simple words; his intelligence quotient, however, was only 45 at the age of 3 years and 5 months.
Methods and results
The activity of DHPR was measured by assay of dried blood spots6 and on cultured fibroblasts. An oral BH4 loading test was given to both patients.'1 As the boy showed no reduction in plasma phenylalanine concentrations he was given 2 mg/kg BH4 intravenously, to which he responded partially (table 2) .
Urine and cerebrospinal fluid (CSF) pterins, CSF neurotransmitter metabolites, homovanillic acid (HVA) and 5-hydroxyndole acetic acid were measured by high performance liquid chromatography with electrochemical detection at high and low plasma concentrations of phenylalanine (table 3) . 12 The urinary and CSF pterin patterns were similar in the two patients, in both of whom the pterin pattern reverted towards normal under dietary treatment. At diagnosis the boy showed (n=20) (n= 11) *Value is mean (SD) (nmol cytochrome C reduced/minute/S mm diameter, filter paper disc). tValue is mean (SD) (nmol NADH oxidised/minute/mg protein). 1:1% of normal activity could be confidently assayed. cause BH4 deficiency, guanosine triphosphate cyclohydrolase I (GTP-CH I) and 6-pyruvoyl tetrahydropterin synthase (PTPS) deficiency causing impaired synthesis and DHPR deficiency causing impaired recycling of the cofactor.4 Further heterogeneity has been described within these defects.'4 The use of a BH4 oral load as a diagnostic tool has shown that a minority of patients deficient in DHPR fail to lower their plasma phenylalanine after loading,4 and in addition it has been shown that some patients have no mutant protein (DHPR-CRM-) in their cells, whereas others have (DHPR-CRM+).3 ' It has been reported that CRM-cases are BH4 responders and CRM+ are non-responders and that the latter have a worse prognosis.9
The present study strengthens the hypothesis that the presence of the mutant DHPR is worse clinically: shown by the earlier onset of symptoms and the relatively poor clinical response to neurotransmitter treatment in the patient with CRM+, although the delay in starting a phenylalanine restricted diet could also have contributed.
Contrary to the opinion that the unresponsiveness to exogenous BH4 could be due to the total deficiency of DHPR catalytic activity,'6 this was present in both our patients and only the child who was CRM+ gave a negative response after oral loading. Unresponsiveness to exogenous BH4 could be due to the binding of cofactor to the mutant enzyme, making BH4 unavailable for hydroxylation. If so, a decrease of plasma phenylalanine might be achieved by loading these patients with doses of BH4 large enough to exceed the CRM+ binding capacity; the CRM+ patient described here did respond to intravenous BH4, and together with another non-responding patient also responded to higher oral doses. 17 Alternative hypotheses might be the production of a reactive pterin, which inactivates hydroxylases, or the inhibition of the hydroxylases by the mutant enzyme. In any of these cases, the endogenous biosynthetic BH4 would be less available in CRM" patients, leading to a worse outcome.
The CRM+ patient described here may have had a more pronounced hydroxylation defect than the child who was CRM-in view of the lower basal concentrations of HVA and 5-HIAA, and the reduced tyrosine production after oral phenylalanine load. Furthermore neonatal hyperphenylalaninaemia has been reported to be higher in patients who were CRM+ than in patients who were CRM-.9
Within the DHPR deficiency the relative frequency of non-responding and responding cases to the oral load of BH4 has been reported in worldwide surveys as 1:3-1:4,4 '4 although this may not be true for the Italian population, as two out of four patients, both originally from Sicily, did not respond to the load.2 A continuum of conditions is to be expected, depending on differences in the mutations. Cases with residual reductase activity" or partial CRM+9 are known to have a milder course. 
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